Approval · Notice of Compliance 2646 · 2001
ORZEL: Notice of Compliance 2646
Issued April 6, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2646
- Date
- April 6, 2001
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Antineoplastic agent and folic acid derivative
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ORZEL | 02243681 | — |
Medicinal ingredients
- LEUCOVORIN CALCIUM 15 MG per TAB
- URACIL 224 MG per CAP
- TEGAFUR 100 MG per KIT